<DOC>
	<DOCNO>NCT02612558</DOCNO>
	<brief_summary>The purpose study evaluate whether fostamatinib safe effective treatment Warm Antibody Autoimmune Hemolytic Anemia ( AIHA ) .</brief_summary>
	<brief_title>A Safety Efficacy Study R935788 Treatment Warm Antibody Autoimmune Hemolytic Anemia ( AIHA )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Anemia , Hemolytic , Autoimmune</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>Subject must diagnosis primary secondary warm antibody AIHA . Must fail least 1 prior treatment regimen AIHA . Subject cold antibody AIHA , cold agglutinin syndrome , mixed type AIHA , paroxysmal cold hemoglobinuria . Subject platelet count &lt; 30,000/μL . Subject AIHA secondary autoimmune disease , include systemic lupus erythematosis ( SLE ) , lymphoid malignancy underlie disease stable wellcontrolled current therapy . Subject uncontrolled poorly control hypertension , define systolic blood pressure ≥ 140 mmHg , diastolic blood pressure ≥ 90 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Warm antibody autoimmune hemolytic anemia ( AIHA )</keyword>
</DOC>